Orality
Model
50%
Speaker Breakdown
HostTracy Alloway(1,061 words)
M:29%
HostJoe Weisenthal(2,345 words)
M:94%
GuestJames van Geelen(7,189 words)
M:94%
Oral Indicators
Agonistic38%
definitely, very, huge
Engagement81%
you, our, your
Memory Aids100%
listen, so, now
Repetition100%
like (332x), know (252x), right (108x)
Parallelism85%
So why would I pay for stuff I..., And I'm Joe Wiesenthal...., And, also, I think there's som...
Sound Patterns100%
151 question(s), alliteration: "markets move", alliteration: "barclays brief"
Formulaic Phrases7%
at the end of the day, you know what, i mean
Literate Indicators
Hedging6%
probably, maybe, could
Passive Voice8%
been taken, be fixed, was approved
Abstract Nouns16%
investment, business, verizon.com/business
Subordination4%
however, because, while
Sentence Length31%
Avg: 12.8 words/sentence
Word Complexity46%
investment, analyze, anticipate
Academic Markers0%
Impersonal Style19%
921 personal pronouns found
Descriptive Style99%
exactly, apply, monthly
Description
There's a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes but have since been found to suppress appetites and induce substantial weight loss. It's a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly all soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of effective weight-loss drugs. He talks us through how he's evaluating the potential of the new meds and how he approaches possible 'mega-trends' like GLP-1 or AI. See omnystudio.com/listener for privacy information.